Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001819790-25-000078
Filing Date
2025-05-01
Accepted
2025-05-01 16:10:36
Documents
79
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tars-20250331.htm   iXBRL 10-Q 1608312
2 EX-31.1 exhibit311-33125.htm EX-31.1 9811
3 EX-31.2 exhibit312-33125.htm EX-31.2 10194
4 EX-32.1 exhibit321-33125.htm EX-32.1 6169
5 EX-32.2 exhibit322-33125.htm EX-32.2 6042
  Complete submission text file 0001819790-25-000078.txt   7882107

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tars-20250331.xsd EX-101.SCH 49753
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT tars-20250331_cal.xml EX-101.CAL 79431
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT tars-20250331_def.xml EX-101.DEF 223928
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tars-20250331_lab.xml EX-101.LAB 681047
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tars-20250331_pre.xml EX-101.PRE 478223
82 EXTRACTED XBRL INSTANCE DOCUMENT tars-20250331_htm.xml XML 1025572
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

EIN.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39614 | Film No.: 25903195
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)